RFS and BCS by Cox univariate analysis in ER positive tumors
| Category | RFS | BCS | ||||
|---|---|---|---|---|---|---|
| RR | 95% CI | p Value | RR | 95% CI | p Value | |
| BCS, breast cancer survival; CI, confidence interval; IDC, invasive ductal carcinomas; ILC, invasive lobular carcinoma; MI, mitotic index; RFS, recurrence free survival; RR, relative risk. | ||||||
| IDC | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.58 | 0.40 to 0.83 | 0.003 | 0.71 | 0.48 to 1.07 | 0.10 |
| ILC | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.79 | 0.26 to 2.36 | 0.67 | 0.91 | 0.28 to 2.99 | 0.88 |
| Low Ki-67 index | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.50 | 0.29 to 0.87 | 0.01 | 0.68 | 0.37 to 1.27 | 0.22 |
| Intermediate Ki-67 index | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 1.15 | 0.61 to 2.17 | 0.66 | 1.40 | 0.69 to 2.71 | 0.37 |
| High Ki-67 index | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.29 | 0.11 to 0.74 | 0.006 | 0.38 | 0.15 to 0.97 | 0.04 |
| MI of 1 | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.63 | 0.34 to 1.16 | 0.14 | 0.57 | 0.28 to 1.12 | 0.13 |
| MI of 2 | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.70 | 0.41 to 1.19 | 0.18 | 1.01 | 0.57 to 1.80 | 0.96 |
| MI of 3 | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.50 | 0.26 to 0.99 | 0.04 | 0.62 | 0.31 to 1.22 | 0.16 |
| Grade I tumours | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.58 | 0.18 to 1.89 | 0.37 | 0.23 | 0.03 to 1.94 | 0.18 |
| Grade II tumours | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.63 | 0.39 to 1.01 | 0.06 | 0.82 | 0.49 to 1.40 | 0.47 |
| Grade III tumours | ||||||
| Control | 1.00 | 1.00 | ||||
| Tamoxifen | 0.50 | 0.29 to 0.87 | 0.01 | 0.59 | 0.34 to 1.04 | 0.07 |